All Stories

  1. Treating liver cancer through arginine depletion
  2. Polyvalency: an emerging trend in the development of clinical antibodies
  3. Towards development of biobetter: L-asparaginase a case study
  4. Engineered polyspecific antibodies: A new frontier in the field of immunotherapeutics
  5. Recombinant human endostatin as a potential anti-angiogenic agent: therapeutic perspective and current status
  6. Development and characterization of fused human arginase I for cancer therapy
  7. Human arginase I: a potential broad-spectrum anti-cancer agent
  8. Fused human paraoxonase 1 as a prophylactic agent against organophosphate poisoning
  9. Polyspecificity - An emerging trend in the development of clinical antibodies
  10. Paraoxonase 1 as a potential prophylactic against nerve agent poisoning
  11. Types of Wound Dressings and Materials used in Mild to Moderately Exuding Wounds: A Review
  12. Apolipoprotein-mimetic Peptides: Current and Future Prospectives
  13. Immunomodulatory potential of apolipoproteins and their mimetic peptides in asthma: Current perspective
  14. Human arginase 1, a Jack of all trades?
  15. Therapeutic potential of ApoE-mimetic peptides in CNS disorders: Current perspective
  16. HDL, ApoA-I and ApoE-Mimetic Peptides: Potential Broad Spectrum Agent for Clinical Use?
  17. Optimization of medium composition to increase the expression of recombinant human interferon-β using the Plackett–Burman and central composite design in E. coli SE1
  18. Human Arginase I (Arg I)—A Potential Broad-spectrum Anti-cancer Agent: Perspectives and the Road Ahead
  19. APOE-Derived Peptides Attenuated Diabetes-Induced Oxidative Stress and Inflammation
  20. Is Human Paraoxonase 1 the Saviour Against the Persistent Threat of Organophosphorus Nerve Agents?
  21. Protein Chimerization: A New Frontier for Engineering Protein Therapeutics with Improved Pharmacokinetics
  22. Antibiotic-free expression system for the production of human interferon-beta protein
  23. Towards Understanding the Catalytic Mechanism of Human Paraoxonase 1: Experimental and In Silico Mutagenesis Studies
  24. Organophosphate-Hydrolyzing Enzymes as First-Line of Defence Against Nerve Agent-Poisoning: Perspectives and the Road Ahead
  25. Refolded Recombinant Human Paraoxonase 1 Variant Exhibits Prophylactic Activity Against Organophosphate Poisoning
  26. Toward Understanding the Catalytic Mechanism of Human Paraoxonase 1: Site-Specific Mutagenesis at Position 192
  27. Abstract 12419: Preclinical Safety and Efficacy of a Novel Thrombolytic Agent Administered by Rapid Bolus Injection: Clot Specific Streptokinase (CSSK/SMRX-11)
  28. Improving Properties of Recombinant SsoPox by Site-Specific Pegylation
  29. Expression and purification of biologically active recombinant human paraoxonase 1 from inclusion bodies of Escherichia coli
  30. Expression, purification and immobilization of recombinant AiiA enzyme onto magnetic nanoparticles
  31. Improving storage stability of recombinant organophosphorus hydrolase
  32. Interplay between amino acid residues at positions 192 and 115 in modulating hydrolytic activities of human paraoxonase 1
  33. Properties of apolipoprotein E derived peptide modulate their lipid-binding capacity and influence their anti-inflammatory function
  34. Stabilization Studies on Bacterially Produced Human Paraoxonase 1 for Improving Its Shelf Life
  35. Human Paraoxonase 1 as a Pharmacologic Agent: Limitations and Perspectives
  36. Apolipoprotein E Derived Peptides Inhibit the Pro-Inflammatory Effect of Lysophosphatidylcholine
  37. Oxidized-phospholipids in reconstituted high density lipoprotein particles affect structure and function of recombinant paraoxonase 1
  38. Characterization of human paraoxonase 1 variants suggest that His residues at 115 and 134 positions are not always needed for the lactonase/arylesterase activities of the enzyme
  39. Differential interaction of peptides derived from C-terminal domain of human apolipoprotein E with platelet activating factor analogs
  40. The Chemical Nature of the Polar Functional Group of Oxidized Acyl Chain Uniquely Modifies the Physicochemical Properties of Oxidized Phospholipid-Containing Lipid Particles
  41. Physicochemical properties of bacterial pro-inflammatory lipids influence their interaction with apolipoprotein-derived peptides
  42. Oxidized phospholipid content destabilizes the structure of reconstituted high density lipoprotein particles and changes their function
  43. Characterization of Oxidized Phospholipid containing Reconstituted High Density Lipoprotein Particle
  44. A Therapeutic Chemical Chaperone Inhibits Cholera Intoxication and Unfolding/Translocation of the Cholera Toxin A1 Subunit
  45. Closely related oxidized phospholipids differentially modulate the physicochemical properties of lipid particles
  46. Membrane lipid composition differentially modulates the function of human plasma platelet activating factor-acetylhydrolase
  47. Contribution of Subdomain Structure to the Thermal Stability of the Cholera Toxin A1 Subunit
  48. Oxidatively modified fatty acyl chain determines physicochemical properties of aggregates of oxidized phospholipids
  49. Stabilization of the Tertiary Structure of the Cholera Toxin A1 Subunit Inhibits Toxin Dislocation and Cellular Intoxication
  50. Peptide derived from the lipid binding domain of Group IB human pancreatic phospholipase A2 possesses antibacterial activity
  51. Membrane surface charge modulates lipoprotein complex forming capability of peptides derived from the C-terminal domain of apolipoprotein E
  52. Preferential binding of apolipoprotein E derived peptides with oxidized phospholipid
  53. Bax C-Terminal Peptide - Insights Into Membrane Interactions
  54. Conformational Instability of the Cholera Toxin A1 Polypeptide
  55. The Pertussis Toxin S1 Subunit Is a Thermally Unstable Protein Susceptible to Degradation by the 20S Proteasome
  56. Isoform-Specific Membrane Insertion of Secretory Phospholipase A2 and Functional Implications
  57. Structural and Functional Effects of Tryptophans Inserted into the Membrane-binding and Substrate-binding Sites of Human Group IIA Phospholipase A2
  58. Carbohydrate-induced modulation of cell membrane. VIII. Agglutination with mammalian lectin galectin-1 increases osmofragility and membrane fluidity of trypsinized erythrocytes
  59. Evidence for the Regulatory Role of the N-terminal Helix of Secretory Phospholipase A2 from Studies on Native and Chimeric Proteins
  60. Positioning Membrane Proteins by Novel Protein Engineering and Biophysical Approaches
  61. Membrane Fluidity Is a Key Modulator of Membrane Binding, Insertion, and Activity of 5-Lipoxygenase
  62. Modulation of Human 5-Lipoxygenase Activity by Membrane Lipids, by
  63. The N-terminal α-Helix of Pancreatic Phospholipase A2 Determines Productive-mode Orientation of the Enzyme at the Membrane Surface
  64. Modulation of Human 5-Lipoxygenase Activity by Membrane Lipids
  65. Oxidation of Goat Hepatic Galectin-1 Induces Change in Secondary Structure
  66. Involvement of a Nine-residue Loop of Streptokinase in the Generation of Macromolecular Substrate Specificity by the Activator Complex through Interaction with Substrate Kringle Domains
  67. Studies on a Doubleheaded Protease Inhibitor from Phaseolus mungo
  68. Carbohydrate induced modulation of cell membrane VII. Binding of exogenous lectin increases osmofragility of erythrocytes
  69. Carbohydrate induced modulation of cell membrane. VI. Binding of exogenous lectin induces susceptibility of erythrocytes to free radical damage: a spin label study